Alcohol septal ablation for obstructive hypertrophic cardiomyopathy
نویسندگان
چکیده
منابع مشابه
Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
Since its original description in 1994, alcohol septal ablation (ASA) has emerged as a minimally invasive modality for treatment of hypertrophic obstructive cardiomyopathy compared to surgical myomectomy. This catheter-based intervention relies on the injection of absolute alcohol into the septal perforator to induce a controlled infarction of the hypertrophied septum and consequently abolish t...
متن کاملAlcohol septal ablation for obstructive hypertrophic cardiomyopathy.
Treatment of obstructive hypertrophic cardiomyopathy remains challenging. Medical therapy, surgical therapy, and pacemaker therapy have been shown to be beneficial in some patients over the years. Alcohol septal ablation is a catheter-based intervention that causes a controlled infarct in the septum leading to a decrease in the left ventricular outflow tract obstruction. Along with the impressi...
متن کاملHypertrophic obstructive cardiomyopathy: alcohol septal ablation
Alcohol septal ablation (ASA) was introduced in 1994 as an alternative to septal myectomy for patients with hypertrophic obstructive cardiomyopathy and symptoms refractory to medical therapy. This procedure alleviates symptoms by producing a targeted, limited infarction of the upper interventricular septum, resulting in an increase in left ventricular outflow tract (LVOT) diameter, a decrease i...
متن کاملSurvival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
BACKGROUND The clinical efficacy of alcohol septal ablation for obstructive hypertrophic cardiomyopathy (HCM) has been demonstrated, but the long-term effects of the procedure remain uncertain. This study examined the survival of patients after septal ablation performed in a tertiary HCM referral center. METHODS AND RESULTS We examined 177 patients (mean age, 64 years; 68% women) who underwen...
متن کاملSurgical Versus Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
Since the original description of hypertrophic cardiomyopathy by Donald Teare1 and Lord Brock2 nearly 50 years ago, management of this condition has attracted the attention of surgeons,3–5 clinical and intervention cardiologists,6–10 epidemiologists, and, more recently, molecular biologists. To date, the emphasis has been directed toward symptomatic patients or those who are at high risk of dyi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Heart
سال: 2006
ISSN: 1355-6037
DOI: 10.1136/hrt.2005.063677